



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

**NASDAQ: CLDX** <sup>1</sup>

Last Trade:	0.64
Trade Time:	4:00 PM ET May 24, 2018
Change:	-0.02  (3.350%)
Day Range	0.62 - 0.68
52-Week Range	0.65 - 3.26
Volume	2,979,800
Market Cap. (\$M)	91.483
Shares Out (M)	143.390

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 16, 2018  
[Celldex Announces Presentations at the 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- May 10, 2018  
[Celldex Provides Corporate Update and Reports First Quarter 2018 Results](#)
- Apr 20, 2018  
[Data from Multiple Celldex Programs Presented at American Association for Cancer Research \(AACR\) Annual Meeting 2018](#)
- Apr 16, 2018  
[Celldex's METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint](#)
- Mar 7, 2018  
[Celldex Provides Corporate Update and Reports Full Year 2017 Results](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [First Quarter Financial Results](#)

- Mar 7, 2018  
[Annual Report \(10-K\)](#)
- Apr 30, 2018  
[Definitive Proxy Statement](#)
- May 10, 2018  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2017  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017  
[Quarterly Report \(10-Q\)](#)